Sponsors

About: We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.

About: QIMR Berghofer has earned its place among Australia’s top medical research institutes with an enviable reputation for ground-breaking and transformative health discoveries. Since 1945, we have embraced new techniques and technologies to advance medical science, leading the way to significant innovation in health – and in doing so, offering hope for a healthier, better tomorrow.

About:

As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to public health through the prevention of influenza and pandemic preparedness. With state-of-the-art production facilities and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

In Australia, CSL Seqirus operates the only manufacturing facility for seasonal and pandemic influenza vaccines, and produces a range of unique medicines in the national interest including antivenoms and the only human vaccine for Q fever. Our commitment to Australia’s health also extends to providing access to paediatric and adult vaccines, and innovative pharmaceuticals for patients living with allergies, cardiovascular disease, severe pain, dry eye disease, iron deficiency, kidney diseases, rare diseases and neurological conditions.

Trade Exhibitors

 About: Biocelect Pty Ltd is a privately owned, full-service Australian pharmaceutical company. We work with local and overseas partners to bring critical pharmaceutical products and medical technology solutions to the Australian market. Our priority areas include infectious diseases, specialty care and in-vitro diagnostics, a portfolio that also enables us to support the Australian Government and key organisations in emergency health planning.

In addition to our travel range, infectious disease portfolio and novel medical diagnostics, Biocelect is the sponsor of the Novavax COVID-19 Vaccine, NVX-CoV2373 for Australia and New Zealand. We are proud to play an important part in our Governments’ COVID-19 management plans by providing options for the vaccine program rollout.

About:

As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to public health through the prevention of influenza and pandemic preparedness. With state-of-the-art production facilities and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

In Australia, CSL Seqirus operates the only manufacturing facility for seasonal and pandemic influenza vaccines, and produces a range of unique medicines in the national interest including antivenoms and the only human vaccine for Q fever. Our commitment to Australia’s health also extends to providing access to paediatric and adult vaccines, and innovative pharmaceuticals for patients living with allergies, cardiovascular disease, severe pain, dry eye disease, iron deficiency, kidney diseases, rare diseases and neurological conditions.

About: The discipline of Public Health and Tropical Medicine at James Cook University focuses on addressing health challenges in tropical, rural and remote regions, with the aim improving health outcomes for underserved populations. It offers a range of postgraduate programs, including the Master of Public Health and Tropical Medicine, which integrates public health principles with specialised knowledge in tropical diseases. Staff within the Discipline are actively engaged in research and work closely with organisations within and beyond Australia. Students are exposed to real-world examples and the subjects allows graduates to approach health challenges from multiple perspectives, including epidemiology, disease control, health promotion, and health policy, making Public Health and Tropical Medicine a leader in preparing graduates to address complex health needs in tropical and remote settings.

ECR Networking Event Sponsor

About: The University of Queensland’s ODeSI team aims to optimise infectious disease prevention, control, and elimination by generating new evidence and providing innovative solutions to support clinical and public health decision-making.

The team develops strong partnerships with clinical and public health decision-makers to co-create and design research, collaborate on the implementation and evaluation of interventions, and explore the application of innovative methods and technologies to disease prevention and control.

Team members have extensive experience with infectious diseases and clinical epidemiology, focusing on neglected tropical diseases, emerging infectious diseases, antimicrobial resistance, vaccine-preventable diseases, travel medicine, global health, digital health, and implementation science.

ECR & Student Prize Sponsor

About: Tropical Medicine and Infectious Disease is an international, scientific, peer-reviewed, open access journal of tropical medicine and infectious disease published monthly online by MDPI. It is the official journal of the Australasian College of Tropical Medicine (ACTM) and its Joint Faculties of Travel Medicine and Expedition and Wilderness Medicine.

Impact Factor: 2.8 (2023); 5-Year Impact Factor: 3.0 (2023)